nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—ABCC8—ATP sensitive Potassium channels—ABCC9—dilated cardiomyopathy	0.0859	0.241	CbGpPWpGaD
Glipizide—KCNJ11—ATP sensitive Potassium channels—ABCC9—dilated cardiomyopathy	0.0833	0.233	CbGpPWpGaD
Glipizide—CYP2C9—cardial valve—dilated cardiomyopathy	0.0573	0.648	CbGeAlD
Glipizide—Glyburide—ABCC9—dilated cardiomyopathy	0.0191	1	CrCbGaD
Glipizide—ABCC8—Inwardly rectifying K+ channels—ABCC9—dilated cardiomyopathy	0.0167	0.0468	CbGpPWpGaD
Glipizide—KCNJ11—Inwardly rectifying K+ channels—ABCC9—dilated cardiomyopathy	0.0162	0.0453	CbGpPWpGaD
Glipizide—ABCC8—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.0148	0.0415	CbGpPWpGaD
Glipizide—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0148	0.0276	CcSEcCtD
Glipizide—Eruption—Furosemide—dilated cardiomyopathy	0.0142	0.0265	CcSEcCtD
Glipizide—Inappropriate antidiuretic hormone secretion—Lisinopril—dilated cardiomyopathy	0.0113	0.0211	CcSEcCtD
Glipizide—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00995	0.0186	CcSEcCtD
Glipizide—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00899	0.0168	CcSEcCtD
Glipizide—PPARG—Nuclear Receptor transcription pathway—NR3C2—dilated cardiomyopathy	0.00864	0.0242	CbGpPWpGaD
Glipizide—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00839	0.0157	CcSEcCtD
Glipizide—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.00821	0.0153	CcSEcCtD
Glipizide—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00803	0.015	CcSEcCtD
Glipizide—Urine output increased—Furosemide—dilated cardiomyopathy	0.0079	0.0148	CcSEcCtD
Glipizide—PPARG—myocardium—dilated cardiomyopathy	0.00775	0.0876	CbGeAlD
Glipizide—KCNJ11—heart—dilated cardiomyopathy	0.0077	0.087	CbGeAlD
Glipizide—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.00747	0.0139	CcSEcCtD
Glipizide—Polyuria—Furosemide—dilated cardiomyopathy	0.00723	0.0135	CcSEcCtD
Glipizide—ABCC8—heart—dilated cardiomyopathy	0.00709	0.0801	CbGeAlD
Glipizide—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00703	0.0131	CcSEcCtD
Glipizide—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00675	0.0126	CcSEcCtD
Glipizide—PPARG—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.00674	0.0189	CbGpPWpGaD
Glipizide—Thirst—Furosemide—dilated cardiomyopathy	0.00667	0.0125	CcSEcCtD
Glipizide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.00659	0.0185	CbGpPWpGaD
Glipizide—ABCC8—Potassium Channels—ABCC9—dilated cardiomyopathy	0.00659	0.0185	CbGpPWpGaD
Glipizide—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00652	0.0122	CcSEcCtD
Glipizide—KCNJ11—Potassium Channels—ABCC9—dilated cardiomyopathy	0.00639	0.0179	CbGpPWpGaD
Glipizide—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00637	0.0119	CcSEcCtD
Glipizide—Malaise—Spironolactone—dilated cardiomyopathy	0.00633	0.0118	CcSEcCtD
Glipizide—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00629	0.0117	CcSEcCtD
Glipizide—Discomfort—Spironolactone—dilated cardiomyopathy	0.00591	0.011	CcSEcCtD
Glipizide—Confusional state—Spironolactone—dilated cardiomyopathy	0.00578	0.0108	CcSEcCtD
Glipizide—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00575	0.0107	CcSEcCtD
Glipizide—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00561	0.0105	CcSEcCtD
Glipizide—PPARG—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00549	0.0154	CbGpPWpGaD
Glipizide—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00545	0.0102	CcSEcCtD
Glipizide—PPARG—heart—dilated cardiomyopathy	0.00541	0.0612	CbGeAlD
Glipizide—Eczema—Lisinopril—dilated cardiomyopathy	0.0053	0.00989	CcSEcCtD
Glipizide—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00527	0.00985	CcSEcCtD
Glipizide—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00513	0.00959	CcSEcCtD
Glipizide—Somnolence—Spironolactone—dilated cardiomyopathy	0.0051	0.00952	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.00501	0.014	CbGpPWpGaD
Glipizide—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00501	0.00935	CcSEcCtD
Glipizide—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00495	0.00924	CcSEcCtD
Glipizide—Drowsiness—Furosemide—dilated cardiomyopathy	0.00489	0.00913	CcSEcCtD
Glipizide—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00488	0.00911	CcSEcCtD
Glipizide—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00478	0.00893	CcSEcCtD
Glipizide—Diplopia—Lisinopril—dilated cardiomyopathy	0.00476	0.00889	CcSEcCtD
Glipizide—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00472	0.00882	CcSEcCtD
Glipizide—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00472	0.00882	CcSEcCtD
Glipizide—Sweating—Furosemide—dilated cardiomyopathy	0.00469	0.00875	CcSEcCtD
Glipizide—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00462	0.00864	CcSEcCtD
Glipizide—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00456	0.00852	CcSEcCtD
Glipizide—Urticaria—Spironolactone—dilated cardiomyopathy	0.00455	0.0085	CcSEcCtD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.00454	0.0127	CbGpPWpGaD
Glipizide—Visual impairment—Furosemide—dilated cardiomyopathy	0.00423	0.0079	CcSEcCtD
Glipizide—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00422	0.00789	CcSEcCtD
Glipizide—Eye disorder—Furosemide—dilated cardiomyopathy	0.0041	0.00766	CcSEcCtD
Glipizide—Pruritus—Spironolactone—dilated cardiomyopathy	0.00406	0.00757	CcSEcCtD
Glipizide—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00392	0.00732	CcSEcCtD
Glipizide—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00392	0.00732	CcSEcCtD
Glipizide—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00391	0.0073	CcSEcCtD
Glipizide—Dysuria—Lisinopril—dilated cardiomyopathy	0.00385	0.00719	CcSEcCtD
Glipizide—PPARG—Noncanonical Wnt signaling pathway—RAC1—dilated cardiomyopathy	0.00384	0.0107	CbGpPWpGaD
Glipizide—Erythema—Furosemide—dilated cardiomyopathy	0.00382	0.00714	CcSEcCtD
Glipizide—Dizziness—Spironolactone—dilated cardiomyopathy	0.00379	0.00708	CcSEcCtD
Glipizide—Flatulence—Furosemide—dilated cardiomyopathy	0.00377	0.00703	CcSEcCtD
Glipizide—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00376	0.00701	CcSEcCtD
Glipizide—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00367	0.00686	CcSEcCtD
Glipizide—Vomiting—Spironolactone—dilated cardiomyopathy	0.00364	0.00681	CcSEcCtD
Glipizide—Rash—Spironolactone—dilated cardiomyopathy	0.00361	0.00675	CcSEcCtD
Glipizide—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00361	0.00674	CcSEcCtD
Glipizide—Vision blurred—Furosemide—dilated cardiomyopathy	0.0036	0.00673	CcSEcCtD
Glipizide—Headache—Spironolactone—dilated cardiomyopathy	0.00359	0.00671	CcSEcCtD
Glipizide—Jaundice—Lisinopril—dilated cardiomyopathy	0.00358	0.00668	CcSEcCtD
Glipizide—Sweating—Lisinopril—dilated cardiomyopathy	0.00352	0.00657	CcSEcCtD
Glipizide—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00347	0.00648	CcSEcCtD
Glipizide—Vertigo—Furosemide—dilated cardiomyopathy	0.00343	0.00641	CcSEcCtD
Glipizide—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00342	0.00639	CcSEcCtD
Glipizide—Leukopenia—Furosemide—dilated cardiomyopathy	0.00342	0.00639	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—GJA1—dilated cardiomyopathy	0.00341	0.00956	CbGpPWpGaD
Glipizide—Nausea—Spironolactone—dilated cardiomyopathy	0.00341	0.00636	CcSEcCtD
Glipizide—Rhinitis—Lisinopril—dilated cardiomyopathy	0.0033	0.00617	CcSEcCtD
Glipizide—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00329	0.00615	CcSEcCtD
Glipizide—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00327	0.0061	CcSEcCtD
Glipizide—CYP2C9—heart—dilated cardiomyopathy	0.00317	0.0358	CbGeAlD
Glipizide—Confusional state—Furosemide—dilated cardiomyopathy	0.00314	0.00587	CcSEcCtD
Glipizide—Shock—Furosemide—dilated cardiomyopathy	0.00307	0.00573	CcSEcCtD
Glipizide—Flushing—Lisinopril—dilated cardiomyopathy	0.00306	0.00571	CcSEcCtD
Glipizide—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00305	0.0057	CcSEcCtD
Glipizide—KCNJ11—Type II diabetes mellitus—TNF—dilated cardiomyopathy	0.00303	0.0085	CbGpPWpGaD
Glipizide—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00302	0.00563	CcSEcCtD
Glipizide—Anorexia—Furosemide—dilated cardiomyopathy	0.00297	0.00555	CcSEcCtD
Glipizide—Chills—Lisinopril—dilated cardiomyopathy	0.00296	0.00552	CcSEcCtD
Glipizide—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00294	0.00549	CcSEcCtD
Glipizide—ABCC8—Neuronal System—ABCC9—dilated cardiomyopathy	0.00288	0.00806	CbGpPWpGaD
Glipizide—Erythema—Lisinopril—dilated cardiomyopathy	0.00287	0.00535	CcSEcCtD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	0.00284	0.00795	CbGpPWpGaD
Glipizide—Flatulence—Lisinopril—dilated cardiomyopathy	0.00283	0.00528	CcSEcCtD
Glipizide—Tension—Lisinopril—dilated cardiomyopathy	0.00281	0.00525	CcSEcCtD
Glipizide—Paraesthesia—Furosemide—dilated cardiomyopathy	0.0028	0.00523	CcSEcCtD
Glipizide—KCNJ11—Neuronal System—ABCC9—dilated cardiomyopathy	0.00279	0.00782	CbGpPWpGaD
Glipizide—Nervousness—Lisinopril—dilated cardiomyopathy	0.00278	0.0052	CcSEcCtD
Glipizide—Somnolence—Furosemide—dilated cardiomyopathy	0.00277	0.00518	CcSEcCtD
Glipizide—ABCC8—Neuronal System—ACTN2—dilated cardiomyopathy	0.00276	0.00773	CbGpPWpGaD
Glipizide—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00276	0.00515	CcSEcCtD
Glipizide—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00271	0.00506	CcSEcCtD
Glipizide—Vision blurred—Lisinopril—dilated cardiomyopathy	0.0027	0.00505	CcSEcCtD
Glipizide—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00269	0.00503	CcSEcCtD
Glipizide—Tremor—Lisinopril—dilated cardiomyopathy	0.00269	0.00502	CcSEcCtD
Glipizide—KCNJ11—Neuronal System—ACTN2—dilated cardiomyopathy	0.00267	0.00749	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—ZIC3—dilated cardiomyopathy	0.00267	0.00749	CbGpPWpGaD
Glipizide—Constipation—Furosemide—dilated cardiomyopathy	0.00267	0.00498	CcSEcCtD
Glipizide—Pain—Furosemide—dilated cardiomyopathy	0.00267	0.00498	CcSEcCtD
Glipizide—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00266	0.00497	CcSEcCtD
Glipizide—PPARG—Wnt Signaling Pathway Netpath—RAC1—dilated cardiomyopathy	0.0026	0.00729	CbGpPWpGaD
Glipizide—Malaise—Lisinopril—dilated cardiomyopathy	0.00259	0.00483	CcSEcCtD
Glipizide—Vertigo—Lisinopril—dilated cardiomyopathy	0.00258	0.00481	CcSEcCtD
Glipizide—Syncope—Lisinopril—dilated cardiomyopathy	0.00257	0.0048	CcSEcCtD
Glipizide—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00257	0.0048	CcSEcCtD
Glipizide—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00257	0.00479	CcSEcCtD
Glipizide—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00255	0.00476	CcSEcCtD
Glipizide—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00252	0.00471	CcSEcCtD
Glipizide—Urticaria—Furosemide—dilated cardiomyopathy	0.00248	0.00463	CcSEcCtD
Glipizide—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00247	0.0046	CcSEcCtD
Glipizide—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00244	0.00456	CcSEcCtD
Glipizide—Myalgia—Lisinopril—dilated cardiomyopathy	0.00244	0.00456	CcSEcCtD
Glipizide—Anxiety—Lisinopril—dilated cardiomyopathy	0.00243	0.00454	CcSEcCtD
Glipizide—Discomfort—Lisinopril—dilated cardiomyopathy	0.00241	0.0045	CcSEcCtD
Glipizide—Confusional state—Lisinopril—dilated cardiomyopathy	0.00236	0.00441	CcSEcCtD
Glipizide—Oedema—Lisinopril—dilated cardiomyopathy	0.00234	0.00437	CcSEcCtD
Glipizide—Shock—Lisinopril—dilated cardiomyopathy	0.0023	0.0043	CcSEcCtD
Glipizide—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.0023	0.00429	CcSEcCtD
Glipizide—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00229	0.00428	CcSEcCtD
Glipizide—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00226	0.00422	CcSEcCtD
Glipizide—PPARG—Transcription factor regulation in adipogenesis—TNF—dilated cardiomyopathy	0.00224	0.00628	CbGpPWpGaD
Glipizide—Asthenia—Furosemide—dilated cardiomyopathy	0.00224	0.00418	CcSEcCtD
Glipizide—Anorexia—Lisinopril—dilated cardiomyopathy	0.00223	0.00417	CcSEcCtD
Glipizide—Pruritus—Furosemide—dilated cardiomyopathy	0.00221	0.00412	CcSEcCtD
Glipizide—PPARG—Adipogenesis—LMNA—dilated cardiomyopathy	0.00218	0.00611	CbGpPWpGaD
Glipizide—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00213	0.00398	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00213	0.00398	CcSEcCtD
Glipizide—Insomnia—Lisinopril—dilated cardiomyopathy	0.00212	0.00395	CcSEcCtD
Glipizide—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.0021	0.00392	CcSEcCtD
Glipizide—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00209	0.0039	CcSEcCtD
Glipizide—Somnolence—Lisinopril—dilated cardiomyopathy	0.00208	0.00388	CcSEcCtD
Glipizide—Dizziness—Furosemide—dilated cardiomyopathy	0.00206	0.00385	CcSEcCtD
Glipizide—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00206	0.00385	CcSEcCtD
Glipizide—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00203	0.0038	CcSEcCtD
Glipizide—PPARG—Developmental Biology—SCN5A—dilated cardiomyopathy	0.00203	0.00568	CbGpPWpGaD
Glipizide—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00202	0.00377	CcSEcCtD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—CD36—dilated cardiomyopathy	0.00202	0.00565	CbGpPWpGaD
Glipizide—Constipation—Lisinopril—dilated cardiomyopathy	0.002	0.00374	CcSEcCtD
Glipizide—Pain—Lisinopril—dilated cardiomyopathy	0.002	0.00374	CcSEcCtD
Glipizide—Vomiting—Furosemide—dilated cardiomyopathy	0.00198	0.0037	CcSEcCtD
Glipizide—Rash—Furosemide—dilated cardiomyopathy	0.00197	0.00367	CcSEcCtD
Glipizide—Dermatitis—Furosemide—dilated cardiomyopathy	0.00196	0.00367	CcSEcCtD
Glipizide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—dilated cardiomyopathy	0.00196	0.00549	CbGpPWpGaD
Glipizide—Headache—Furosemide—dilated cardiomyopathy	0.00195	0.00365	CcSEcCtD
Glipizide—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00193	0.0036	CcSEcCtD
Glipizide—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00191	0.00357	CcSEcCtD
Glipizide—Urticaria—Lisinopril—dilated cardiomyopathy	0.00186	0.00347	CcSEcCtD
Glipizide—Nausea—Furosemide—dilated cardiomyopathy	0.00185	0.00346	CcSEcCtD
Glipizide—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00185	0.00345	CcSEcCtD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00181	0.00507	CbGpPWpGaD
Glipizide—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00172	0.00322	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00171	0.00479	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.0017	0.00477	CbGpPWpGaD
Glipizide—Asthenia—Lisinopril—dilated cardiomyopathy	0.00168	0.00314	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00166	0.00466	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00166	0.00466	CbGpPWpGaD
Glipizide—Pruritus—Lisinopril—dilated cardiomyopathy	0.00166	0.00309	CcSEcCtD
Glipizide—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.0016	0.00299	CcSEcCtD
Glipizide—Dizziness—Lisinopril—dilated cardiomyopathy	0.00155	0.00289	CcSEcCtD
Glipizide—ABCC8—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00155	0.00433	CbGpPWpGaD
Glipizide—PPARG—PPARA activates gene expression—CD36—dilated cardiomyopathy	0.00152	0.00425	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—NR3C2—dilated cardiomyopathy	0.00149	0.00418	CbGpPWpGaD
Glipizide—Vomiting—Lisinopril—dilated cardiomyopathy	0.00149	0.00278	CcSEcCtD
Glipizide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	0.00148	0.00416	CbGpPWpGaD
Glipizide—Rash—Lisinopril—dilated cardiomyopathy	0.00148	0.00276	CcSEcCtD
Glipizide—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00147	0.00275	CcSEcCtD
Glipizide—Headache—Lisinopril—dilated cardiomyopathy	0.00147	0.00274	CcSEcCtD
Glipizide—PPARG—Regulation of retinoblastoma protein—RAF1—dilated cardiomyopathy	0.00143	0.00399	CbGpPWpGaD
Glipizide—Nausea—Lisinopril—dilated cardiomyopathy	0.00139	0.0026	CcSEcCtD
Glipizide—PPARG—PPARA activates gene expression—AGT—dilated cardiomyopathy	0.00136	0.00382	CbGpPWpGaD
Glipizide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	0.00134	0.00374	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—FAS—dilated cardiomyopathy	0.00127	0.00357	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—AGT—dilated cardiomyopathy	0.00119	0.00335	CbGpPWpGaD
Glipizide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	0.00116	0.00326	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—ANKRD1—dilated cardiomyopathy	0.00112	0.00315	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—ANKRD1—dilated cardiomyopathy	0.00109	0.00305	CbGpPWpGaD
Glipizide—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00108	0.00302	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—TAZ—dilated cardiomyopathy	0.00106	0.00296	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—TAZ—dilated cardiomyopathy	0.00103	0.00287	CbGpPWpGaD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	0.00102	0.00286	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—SDHA—dilated cardiomyopathy	0.000956	0.00268	CbGpPWpGaD
Glipizide—PPARG—Generic Transcription Pathway—NPPA—dilated cardiomyopathy	0.000937	0.00263	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—SDHA—dilated cardiomyopathy	0.000927	0.0026	CbGpPWpGaD
Glipizide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	0.00092	0.00258	CbGpPWpGaD
Glipizide—PPARG—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000899	0.00252	CbGpPWpGaD
Glipizide—PPARG—Signaling events mediated by HDAC Class I—TNF—dilated cardiomyopathy	0.000888	0.00249	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000854	0.00239	CbGpPWpGaD
Glipizide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—dilated cardiomyopathy	0.000823	0.00231	CbGpPWpGaD
Glipizide—PPARG—Metabolism—ANKRD1—dilated cardiomyopathy	0.000806	0.00226	CbGpPWpGaD
Glipizide—PPARG—Metabolism—TAZ—dilated cardiomyopathy	0.000758	0.00212	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—NR3C2—dilated cardiomyopathy	0.000718	0.00201	CbGpPWpGaD
Glipizide—PPARG—Metabolism—SDHA—dilated cardiomyopathy	0.000685	0.00192	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000666	0.00187	CbGpPWpGaD
Glipizide—ABCC8—Neuronal System—RAF1—dilated cardiomyopathy	0.000628	0.00176	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000626	0.00176	CbGpPWpGaD
Glipizide—KCNJ11—Neuronal System—RAF1—dilated cardiomyopathy	0.000609	0.00171	CbGpPWpGaD
Glipizide—PPARG—Adipogenesis—TNF—dilated cardiomyopathy	0.000541	0.00152	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000534	0.0015	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—CD36—dilated cardiomyopathy	0.000456	0.00128	CbGpPWpGaD
Glipizide—PPARG—Gene Expression—NPPA—dilated cardiomyopathy	0.000451	0.00126	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—RAC1—dilated cardiomyopathy	0.000429	0.0012	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000418	0.00117	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000407	0.00114	CbGpPWpGaD
Glipizide—PPARG—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000366	0.00103	CbGpPWpGaD
Glipizide—ABCC8—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000337	0.000945	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000297	0.000831	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—RAF1—dilated cardiomyopathy	0.000285	0.000798	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000279	0.000782	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—GPX1—dilated cardiomyopathy	0.00026	0.000728	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—CD36—dilated cardiomyopathy	0.000253	0.000709	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.000252	0.000707	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—GPX1—dilated cardiomyopathy	0.000252	0.000706	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—CD36—dilated cardiomyopathy	0.000245	0.000687	CbGpPWpGaD
Glipizide—ABCC8—Metabolism—AGT—dilated cardiomyopathy	0.000228	0.000638	CbGpPWpGaD
Glipizide—KCNJ11—Metabolism—AGT—dilated cardiomyopathy	0.000221	0.000619	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000196	0.000548	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—EGFR—dilated cardiomyopathy	0.000195	0.000547	CbGpPWpGaD
Glipizide—PPARG—Metabolism—GPX1—dilated cardiomyopathy	0.000186	0.000522	CbGpPWpGaD
Glipizide—PPARG—Developmental Biology—TNF—dilated cardiomyopathy	0.000186	0.000521	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	0.000184	0.000516	CbGpPWpGaD
Glipizide—PPARG—Metabolism—CD36—dilated cardiomyopathy	0.000181	0.000508	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	0.000166	0.000466	CbGpPWpGaD
Glipizide—PPARG—Metabolism—AGT—dilated cardiomyopathy	0.000163	0.000457	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000154	0.000431	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00015	0.00042	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000135	0.000378	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	6.85e-05	0.000192	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	6.68e-05	0.000187	CbGpPWpGaD
Glipizide—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	6.01e-05	0.000168	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.52e-05	0.000127	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.4e-05	0.000123	CbGpPWpGaD
Glipizide—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	3.96e-05	0.000111	CbGpPWpGaD
